Novast leverages its state-of-the-art facilities and a pioneering team to introduce advanced generic drugs to the U.S. market through strategic collaborations. Specializing in the research, development, and production of value-added generic drugs, Novast targets the U.S. pharmaceutical market in partnership with leading channels.
As the first Chinese pharmaceutical company to sell products in the U.S., Novast collaborates with U.S. sales channels and original development enterprises. Its 18,000 square meters cGMP manufacturing facilities and a management team with extensive experience set the company apart, having applied for over 100 generic drug patents in the U.S.
Founded in 2005, Novast continues to grow in the Health Care, Manufacturing, and Pharmaceutical sectors. The company's last major infusion of capital was a CNY400.00M Venture Round investment on January 29, 2021, from investors HighLight Capital and Shiyu Capital.
.-logo.jpg "Pii (Pharmaceutics International, Inc.)"){kind=logo}
